Interim Analysis of Phase 2 Results for Cemiplimab in Patients with Metastatic Basal Cell Carcinoma (mBCC) who Progressed on or are Intolerant to Hedgehog Inhibitors (HHIs). J of Skin [Internet]. 2021 Jan. 1 [cited 2025 Apr. 19];5(1):s3. Available from: https://skin.dermsquared.com/skin/article/view/1155